0001209191-17-007053.txt : 20170202 0001209191-17-007053.hdr.sgml : 20170202 20170202160305 ACCESSION NUMBER: 0001209191-17-007053 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170131 FILED AS OF DATE: 20170202 DATE AS OF CHANGE: 20170202 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: bluebird bio, Inc. CENTRAL INDEX KEY: 0001293971 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 150 SECOND STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 339-499-9300 MAIL ADDRESS: STREET 1: 150 SECOND STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 FORMER COMPANY: FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc DATE OF NAME CHANGE: 20040616 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mandell James CENTRAL INDEX KEY: 0001595896 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35966 FILM NUMBER: 17568279 MAIL ADDRESS: STREET 1: GOODWIN PROCTER LLP STREET 2: 53 STATE STREET CITY: BOSTON STATE: MA ZIP: 02109 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-01-31 0 0001293971 bluebird bio, Inc. BLUE 0001595896 Mandell James C/O BLUEBIRD BIO, INC. 150 SECOND STREET CAMBRIDGE MA 02141 1 0 0 0 Common Stock 2017-01-31 4 M 0 8000 21.43 A 9000 D Common Stock 2017-01-31 4 S 0 8000 75.0402 D 1000 D Stock Option (right to buy) 21.43 2017-01-31 4 M 0 8000 0.00 A 2024-01-08 Common Stock 8000 4000 D This sales reported in the Form 4 were effectd pursuant to a 10b5-1 trading plan adopted by the reporting person on December 13, 2016. The range in prices for the transaction reported on this line was $75.00 to $75.20. The average weighted price was $75.0402. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. This option vests ratably over three years in annual installments, commencing on January 8, 2014. /s/ Jason F. Cole, Attorney-in-Fact 2017-02-02